phrykt

Arrowhead Pharmaceuticals, Inc. (ARWR): who owns it and who trades it

As of Nov 16, 2026, ARWR insiders reported 64 open-market sales worth $37.3M and no purchases in the last 12 months, with 45% of the sale value made under pre-set 10b5-1 plans. The largest seller was Christopher Richard Anzalone (CEO), with $24M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Arrowhead Pharmaceuticals

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ARWR

498 funds and institutions reported ARWR shares worth $9.8B at the end of Q2 2026, about 85% of the company. The largest holder is BlackRock, Inc. with 10.5%.

Funds and institutions (13F) 85%Everyone else 15%

10 largest owners, by share of the company

BlackRock, Inc.10.5%
Avoro Capital Advisors LLC8.1%
FMR LLC (Fidelity)5.7%
Vanguard Portfolio Management LLC4.5%
Vanguard Capital Management LLC4.3%
State Street Corp4.0%
Norges Bank2.8%
Invesco Ltd.2.8%
Geode Capital Management, LLC2.5%
Fred Alger Management, LLC2.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.14.83M10.53%$1.2B-18%
Avoro Capital Advisors LLC11.36M8.06%$926M+6%
FMR LLC (Fidelity)8.04M5.71%$655M+11%
Vanguard Portfolio Management LLC6.35M4.51%$518M-11%
Vanguard Capital Management LLC6.11M4.34%$498M+1%
State Street Corp5.69M4.04%$464M-12%
Norges Bank3.90M2.77%$318M–
Invesco Ltd.3.88M2.76%$317M+18%
Geode Capital Management, LLC3.53M2.51%$299M-17%
Fred Alger Management, LLC3.30M2.34%$269M-1%
Baker Bros. Advisors LP1.99M1.41%$162MNo change
Siren, L.L.C.1.72M1.22%$140M+6%
Vestal Point Capital, LP1.57M1.12%$128M-31%
Deerfield Management Company, L.P.1.39M0.99%$113M-12%
First Trust Advisors LP1.35M0.96%$110M+807%
Driehaus Capital Management LLC1.35M0.96%$110M+13%
Jupiter Topco LLC1.22M0.87%$99.6M–
Northern Trust Corp1.19M0.85%$97.2M-28%
Dimensional Fund Advisors LP1.18M0.84%$96.3M+94%
Goldman Sachs Group Inc1.15M0.82%$93.7M-34%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ARWR insiders reported $0 of open-market purchases and $37.3M of sales. 45% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$37.3M
64 trades, 10 people
Sales under a 10b5-1 plan
45%
Share of sale value
Latest trade
Aug 18, 2026
Filed Aug 20, 2026

Purchases and sales by month

$26.6M$26.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 18, 2026Adeoye Y OlukotunDirectorSale2,000$86.96$174KForm 4
Aug 18, 2026Michael S PerryDirectorSale11,600$87.30$1MForm 4
May 12, 2026Hongbo LuDirectorSale plan2,970$76.88$228KForm 4
Apr 23, 2026James C HamiltonChief Medical OfficerSale plan10,000$75.00$750KForm 4
Apr 22, 2026Daniel Joseph ApelCFOSale plan8,730$71.92$628KForm 4
Apr 22, 2026Daniel Joseph ApelCFOSale plan1,157$70.45$81.5KForm 4
Apr 22, 2026Daniel Joseph ApelCFOSale plan3,208$70.11$225KForm 4
Mar 5, 2026James C HamiltonChief Medical OfficerSale plan10,000$64.19$642KForm 4
Jan 5, 2026Patrick O'BrienCOOSale plan46$68.00$3.1KForm 4
Jan 5, 2026Patrick O'BrienCOOSale plan4,368$61.20$267KForm 4
Jan 5, 2026Patrick O'BrienCOOSale plan6,164$62.23$384KForm 4
Jan 5, 2026Patrick O'BrienCOOSale plan13,451$62.96$847KForm 4
Jan 5, 2026Patrick O'BrienCOOSale plan11,842$63.84$756KForm 4
Jan 5, 2026Patrick O'BrienCOOSale plan2,700$64.44$174KForm 4
Jan 5, 2026Patrick O'BrienCOOSale plan900$66.01$59.4KForm 4
Jan 5, 2026Patrick O'BrienCOOSale plan313$68.00$21.3KForm 4
Jan 5, 2026Patrick O'BrienCOOSale plan600$61.12$36.7KForm 4
Jan 5, 2026Patrick O'BrienCOOSale plan900$62.25$56KForm 4
Jan 5, 2026Patrick O'BrienCOOSale plan5,873$62.91$369KForm 4
Jan 5, 2026Patrick O'BrienCOOSale plan2,336$64.04$150KForm 4
Jan 5, 2026James C HamiltonChief Medical OfficerSale plan4,625$61.24$283KForm 4
Jan 5, 2026James C HamiltonChief Medical OfficerSale plan6,090$62.28$379KForm 4
Jan 5, 2026James C HamiltonChief Medical OfficerSale plan14,792$63.01$932KForm 4
Jan 5, 2026James C HamiltonChief Medical OfficerSale plan309$68.00$21KForm 4
Jan 5, 2026James C HamiltonChief Medical OfficerSale plan1,200$64.49$77.4KForm 4
Jan 5, 2026James C HamiltonChief Medical OfficerSale plan437$65.97$28.8KForm 4
Jan 5, 2026James C HamiltonChief Medical OfficerSale plan12,711$63.95$813KForm 4
Jan 2, 2026Christopher Richard AnzaloneCEOSale plan5,771$66.39$383KForm 4
Jan 2, 2026Christopher Richard AnzaloneCEOSale plan7,416$65.88$489KForm 4
Dec 29, 2025Christopher Richard AnzaloneCEOSale plan16,545$68.69$1.1MForm 4
Dec 29, 2025Christopher Richard AnzaloneCEOSale plan35,181$69.33$2.4MForm 4
Dec 26, 2025Mauro FerrariDirectorSale plan7,530$70.00$527KForm 4
Dec 22, 2025Christopher Richard AnzaloneCEOSale plan2,574$68.85$177KForm 4
Dec 22, 2025Christopher Richard AnzaloneCEOSale plan10,012$68.33$684KForm 4
Dec 19, 2025William D. WaddillDirectorSale plan5,451$68.01$371KForm 4
Dec 19, 2025William D. WaddillDirectorSale plan2,416$66.66$161KForm 4
Dec 19, 2025William D. WaddillDirectorSale plan500$68.53$34.3KForm 4
Dec 19, 2025Victoria VakienerDirectorSale plan2,799$66.63$186KForm 4
Dec 19, 2025Victoria VakienerDirectorSale plan1,960$68.39$134KForm 4
Dec 19, 2025Victoria VakienerDirectorSale plan5,281$67.97$359KForm 4
Dec 19, 2025Christopher Richard AnzaloneCEOSale plan3,979$66.67$265KForm 4
Dec 19, 2025Christopher Richard AnzaloneCEOSale plan8,147$68.01$554KForm 4
Dec 19, 2025Christopher Richard AnzaloneCEOSale plan1,319$68.48$90.3KForm 4
Dec 19, 2025Adeoye Y OlukotunDirectorSale plan3,090$66.70$206KForm 4
Dec 19, 2025Adeoye Y OlukotunDirectorSale plan6,083$68.04$414KForm 4
Dec 19, 2025Adeoye Y OlukotunDirectorSale plan827$68.48$56.6KForm 4
Dec 17, 2025Christopher Richard AnzaloneCEOSale35,750$64.51$2.3MForm 4
Dec 17, 2025Christopher Richard AnzaloneCEOSale982$65.53$64.4KForm 4
Dec 17, 2025Christopher Richard AnzaloneCEOSale1,981$66.30$131KForm 4
Dec 17, 2025Christopher Richard AnzaloneCEOSale46,287$63.55$2.9MForm 4
Dec 16, 2025Christopher Richard AnzaloneCEOSale3,221$67.87$219KForm 4
Dec 16, 2025Christopher Richard AnzaloneCEOSale166$66.77$11.1KForm 4
Dec 16, 2025Christopher Richard AnzaloneCEOSale1,300$65.77$85.5KForm 4
Dec 16, 2025Christopher Richard AnzaloneCEOSale1,000$64.96$65KForm 4
Dec 16, 2025Christopher Richard AnzaloneCEOSale8,476$62.94$533KForm 4
Dec 16, 2025Christopher Richard AnzaloneCEOSale14,095$62.12$876KForm 4
Dec 16, 2025Christopher Richard AnzaloneCEOSale10,963$61.25$671KForm 4
Dec 16, 2025Christopher Richard AnzaloneCEOSale8,416$60.51$509KForm 4
Dec 16, 2025Christopher Richard AnzaloneCEOSale6,661$64.29$428KForm 4
Dec 15, 2025Christopher Richard AnzaloneCEOSale8,147$69.96$570KForm 4
Dec 15, 2025Christopher Richard AnzaloneCEOSale21,321$69.28$1.5MForm 4
Dec 15, 2025Christopher Richard AnzaloneCEOSale100,532$68.67$6.9MForm 4
Dec 5, 2025Michael S PerryDirectorSale16,250$61.03$992KForm 4
Nov 28, 2025Mauro FerrariDirectorSale8,750$56.39$493KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Christopher Richard AnzaloneChief Executive Officer, Director–$24MJan 2, 2026
James C HamiltonChief Medical Officer–$3.9MApr 23, 2026
Patrick O'BrienCOO–$3.1MJan 5, 2026
Michael S PerryDirector–$2MAug 18, 2026
Mauro FerrariDirector–$1MDec 26, 2025
Daniel Joseph ApelChief Financial Officer–$934KApr 22, 2026
Adeoye Y OlukotunDirector–$851KAug 18, 2026
Victoria VakienerDirector–$679KDec 19, 2025
William D. WaddillDirector–$566KDec 19, 2025
Hongbo LuDirector–$228KMay 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ARWR short interest

Moderate short interest. 8.2% of ARWR shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 10%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 11.58M ARWR shares were sold short, 8.2% of the shares outstanding, up 5.7% from the report before. At the average daily volume of 1.36M shares, buying them all back would take about 8.5 trading days (days to cover).

Shares short, % of all shares

8.20%May 15Oct 309.66%

Days to cover

8.5May 15Oct 309.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202611.58M8.20%+6%1.36M8.5
Oct 15, 202610.96M7.76%+2%2.05M5.4
Sep 30, 202610.76M7.62%+16%2.67M4.0
Sep 15, 20269.27M6.56%-2%1.80M5.2
Aug 31, 20269.43M6.67%+2%1.07M8.8
Aug 14, 20269.21M6.52%-5%1.18M7.8
Jul 31, 20269.66M6.84%+0%2.51M3.9
Jul 15, 20269.64M6.84%+14%1.98M4.9
Jun 30, 20268.43M5.99%-28%3.82M2.2
Jun 15, 202611.74M8.33%-5%1.43M8.2
May 29, 202612.39M8.80%-4%1.49M8.3
May 15, 202612.93M9.18%-0%1.84M7.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Arrowhead Pharmaceuticals company events

Arrowhead Pharmaceuticals filed 11 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026AgreementArrowhead Pharmaceuticals, Inc. and its subsidiary, Arrowhead Madison Inc., as guarantor, refinanced its senior secured term loans under the Existing Financing Agreement (defined below) by entering into an Amended and Restated Financing Agreement with the lenders party thereto and Sixth Street… Filing
  2. Aug 4, 2026ResultsReleased financial results. Filing
  3. Jun 16, 2026LeadershipThe Board of Directors of Arrowhead Pharmaceuticals, Inc. appointed Dr. Matt Cohen, M.D., M.B.A., as a director of the Company, effective June 12, 2026. Filing
  4. May 7, 2026ResultsReleased financial results. Filing
  5. Mar 20, 2026VoteReported shareholder vote results. Filing
  6. Feb 5, 2026ResultsReleased financial results. Filing
  7. Jan 12, 2026AgreementArrowhead Pharmaceuticals, Inc. issued $700 million of its 0.00% Convertible Senior Notes due 2032. Filing
  8. Jan 9, 2026AgreementArrowhead Pharmaceuticals, Inc. entered into an underwriting agreement with Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein, to issue and sell 3,100,776 shares of the Company’s common stock, $0.001 par value per share, at a public offering… Filing
  9. Jan 6, 2026AnnouncementThe Company announced interim results from its Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7. Filing
  10. Nov 25, 2025ResultsReleased financial results. Filing
  11. Nov 18, 2025AnnouncementArro whead Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved REDEMPLO ® (plozasiran) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Arrowhead Pharmaceuticals financials

Famous investors that hold ARWR

5 of the 50 well-known investors we track reported holding ARWR in their latest 13F filing. The largest position is Ken Fisher's, worth $58.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Fisher · Fisher Asset ManagementQ3 2026893,700$58.5M0.0%-7%
Israel Englander · Millennium ManagementQ3 2026497,587$32.6M0.0%+51%
Ken Griffin · Citadel AdvisorsQ3 2026197,656$12.9M0.0%New
Jim Simons · Renaissance TechnologiesQ3 202634,000$2.2M0.0%-93%
Paul Tudor Jones · Tudor Investment CorpQ3 202610,556$691K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ARWR in the last 120 days.

FiledHolderFormStake
Nov 5, 2026FMR LLC13G/A6.6%
Nov 5, 2026FMR LLC13G/A6.6%

Questions about Arrowhead Pharmaceuticals, Inc. (ARWR) stock

Who owns the most ARWR stock?

The largest reported owner of Arrowhead Pharmaceuticals, Inc. (ARWR) is BlackRock, Inc., with 10.5% of the company. In total, 498 funds and institutions reported holding ARWR at the end of Q2 2026, together about 85% of the shares. See the largest owners.

Are ARWR insiders buying or selling?

In the last 12 months, ARWR insiders reported no open-market purchases and 64 sales worth $37.3M. The latest trade was on Aug 18, 2026. See every trade.

What is the short interest in ARWR?

As of Oct 30, 2026, 11.58M ARWR shares were sold short, 8.2% of the shares outstanding, up 5.7% from the report before. At the average daily volume of 1.36M shares, buying them all back would take about 8.5 trading days (days to cover). See the history.

Which famous investors hold ARWR?

5 of the 50 well-known investors we track reported ARWR in their latest 13F filing, including Ken Fisher, Israel Englander, Ken Griffin. The largest position is worth $58.5M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.